Critical Outcome Technologies preclinical data

In a mouse model of ovarian cancer, 40 mg/kg IV COTI-2 daily for 5 days/week produced a significantly greater complete remission (CR) rate vs. vehicle-treated controls (30% vs. 0%, p<0.01). However, 2...